Bone Biologics Corporation Statistics
Share Statistics
Bone Biologics Corporation has 43.85K shares outstanding. The number of shares has increased by -30.26% in one year.
| Shares Outstanding | 43.85K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 8.51% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.11K |
| Failed to Deliver (FTD) Shares | 147 |
| FTD / Avg. Volume | 57.87% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.13 and the forward PE ratio is null.
| PE Ratio | -0.13 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.41 |
| P/FCF Ratio | -0.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bone Biologics Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.08% and return on capital (ROIC) is -324.4%.
| Return on Equity (ROE) | -3.08% |
| Return on Assets (ROA) | -2.39% |
| Return on Capital (ROIC) | -324.4% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -4.47M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 976.36% in the last 52 weeks. The beta is 0.74, so Bone Biologics Corporation's price volatility has been higher than the market average.
| Beta | 0.74 |
| 52-Week Price Change | 976.36% |
| 50-Day Moving Average | 32.71 |
| 200-Day Moving Average | 22.96 |
| Relative Strength Index (RSI) | 95.75 |
| Average Volume (20 Days) | 254 |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -9.43M |
| Net Income | -8.95M |
| EBITDA | 479.57K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -34.01 |
Balance Sheet
The company has 3.03M in cash and 0 in debt, giving a net cash position of 3.03M.
| Cash & Cash Equivalents | 3.03M |
| Total Debt | 0 |
| Net Cash | 3.03M |
| Retained Earnings | -80.91M |
| Total Assets | 4.07M |
| Working Capital | 3.79M |
Cash Flow
In the last 12 months, operating cash flow was -9.56M and capital expenditures 0, giving a free cash flow of -9.56M.
| Operating Cash Flow | -9.56M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.56M |
| FCF Per Share | -36.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BBLGW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -57.45% |
| FCF Yield | -350.1% |
Analyst Forecast
Currently there are no analyst rating for BBLGW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 7, 2023. It was a backward split with a ratio of 1:30.
| Last Split Date | Jun 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -24.27 |
| Piotroski F-Score | 1 |